RxDoctor Payments Data

Michael Kuhlenschmidt, MD

Internal Medicine · Mahomet, ILNPI 1588046288

Payments from drug & device makers

$2,074in general payments, 2019–2025

Across 150 payments — averaging $13.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$400
  • Lilly USA, LLC$314
  • Novo Nordisk$192
  • AstraZeneca$183
  • Amarin Pharma, Inc.$159
  • Johnson & Johnson$142
  • plus $684 from 16 others

What the payments were for

  • Food & beverage$2,00597%
  • Education$693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,074 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$183,202
Medicare patients
320
Services billed
7,904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$138,710
TrulicityDulaglutide77$84,370
OzempicSemaglutide65$73,848
JardianceEmpagliflozin37$62,426
XareltoRivaroxaban49$61,582
MounjaroTirzepatide55$58,928
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$47,767
Repatha SureclickEvolocumab55$47,496
JanuviaSitagliptin Phosphate15$24,623
MyrbetriqMirabegron18$24,272
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,434
ProtonixPantoprazole Sodium13$11,218
Humalog Kwikpen U-100Insulin Lispro17$8,915
Praluent PenAlirocumab16$8,751
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$7,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Protonix$116$149,929131 claims
Lilly USA, LLCTrulicity, Mounjaro$314$143,299132 claims
Novo NordiskOzempic$192$73,84865 claims
Boehringer IngelheimJardiance$75$62,42637 claims
Johnson & JohnsonXarelto$142$61,58249 claims
GSKTrelegy Ellipta, Anoro Ellipta$14$55,49575 claims
MerckJanuvia$48$24,62315 claims
AstraZenecaBreztri Aerosphere$183$14,43415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Mahomet

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →